BETA
Your AI-Trained Oncology Knowledge Connection!
Ellen Marin, PA-C, presents the study conclusions and discusses its implications on managing CRS associated with teclistamab with Dr. Lonial.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Elranatamab and MagnetisMM-3 Results are Superior to Real-World Multiple Myeloma Outcomes
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Carfilzomib Regimens Improve MRD Outcomes in Older, Fit NDMM Population
Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma